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A b s t r a c t  
Combination of natural compounds and cytotoxic drugs represents a logical therapeutic approach 
for breast cancer. Brucine, a natural plant alkaloid is reported to possess cytotoxic, anti-
inflammatory and anti-cancer activities. Gemcitabine is a nucleoside analog, commonly used in the 
treatment of several solid tumors, including breast cancer. In the present study we have examined 
the anticancer effect of brucine and gemcitabine on MDA MB-231 human breast cancer cells. Cell 
proliferation was assessed using MTT assay. Soft agar assay was used to evaluate the in-vitro 
clonogencity of MDA MB-231 cells. Cell migration was determined by in-vitro scratch assay and 
expression of p65 (NF-kB subunit) was evaluated by western blot analysis. Combination treatment 
with brucine and gemcitabine resulted in a significant inhibition of cell proliferation than either 
brucine or gemcitabine alone. Cells treated with combination of brucine and gemcitabine showed 
additive inhibition in colony formation and cell migration than treated with individual agents. The cells 
treated with brucine at 300 øM showed a significant decrease in p65-NF-kB expression but in 
combination treatment there was no additive inhibition of p65 expression compared to brucine 
treated cells. Overall, our results suggested that brucine in combination with gemcitabine showed 
supra-additive anticancer effects in MDA MB-231 cells and warrants further in-vivo studies in 
experimental animal models. 
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Introduction 
Breast cancer is the common cause of cancer death in women [1]. 
Globally, every year more than one million women are diagnosed 
with breast cancer and more than 410000 are likely to die from the 
disease [2]. Present therapies include surgery, radiation and 
chemotherapeutic agents and there are limitations with these and 
side effects are common. Currently gemcitabine is used for breast 
cancer [3]. However gemcitabine treatment results in only marginal 
survival advantage and is associated with many side effects 
including development of drug resistance [3]. Thus there is need 
for the development of new therapeutic agents and testing new 
compounds isolated from plants with the existing anticancer agents 
are anticipated to show better outcome. 
Many compounds derived from plants, such as taxanes (docetaxel, 
paclitaxel), vinca alkaloids (vindesine) and anthracyclines 
(epirubicin) are known anticancer agents [4, 5]. Brucine is a natural 
plant alkaloid isolated from the seeds of medicinal herb Strychnos 
nux-vomica [6]. It has been used for the treatment of liver cancer in 
Chinese medicine. Recent studies found that brucine has anti-
proliferative effects in different cancer cell lines [7-11] and it 
induces cell death by arresting the cell cycle at G1 phase in colon 
cancer cells [12]. Previous reports revealed brucine has analgesic 
and anti-inflammation [13] properties.   
Gemcitabine (2Ê2Ê-difluorodeoxycytidine) is an analogue of 
deoxycytidine which is used as a chemotherapeutic drug for the 
treatment of various cancers. Although it is inactive in native form, 
it is progressively phosphorylated to the active triphosphate form 
[14] which is incorporated into as fraudulent base in competition 
with dCTP resulting in DNA chain termination. Gemcitabine is used 
for the treatment of pancreatic cancer [15] and in combination for 
non-small cell lung cancer [16]. Gemcitabine in combination with 
natural compounds such as curcumin showed enhanced 
anticancer activity in pancreatic [17] and bladder cancer [18]. A 
major reason for failure of breast cancer therapy is due to 
development of drug resistance. Cell proliferation and 
chemoresistance in breast cancer cells have been linked to 
transcription factor nuclear factor-kB (NF-kB) [19]. Brucine chemo-
sensitizes human lung cancer cells by inhibition of NF-kB [20]. The 
combination of brucine and gemcitabine has not been tested. In the 
present study we investigated the anticancer effect of brucine in 
combination with gemcitabine in MDA MB-231 breast cancer cells.   
Materials and methods 
Cell lines and culture conditions 
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The human breast cancer cell line (MDA MB-231) was acquired 
from the American Type Culture Collection (ATTC, Manassas, VA), 
and was maintained in DMEM culture medium supplemented with 
10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37ĈC 
in  incubator supplied with 5% CO2.  
Drugs and reagents 
Brucine and gemcitabine were received as a powder from Sigma-
Aldrich (St. Louis, MO, USA). Brucine (50 mM) and gemcitabine 
(10 mM) stocks were prepared in dimethyl sulfoxide (DMSO; 
Merck, Darmstadt, Germany) and phosphate buffer saline pH 7.2 
(PBS), respectively, and stored at -20ÀC until use. DulbeccoÊs 
modified EagleÊs medium (DMEM), Fetal Bovine Serum (FBS), 
trypsin, penicillin and streptomycin were purchased from Gibco-
BRL (Grand Island, NY, USA). MTT was purchased from Sigma-
Aldrich (St. Louis, MO, USA). Antibodies against p65 (NF-kB) and 
goat anti-rabbit IgG were obtained from Santa Cruz Biotechnology 
(SantaCruz, CA, US). All other chemicals of analytical grade were 
purchased from Sigma, USA. 
Determination of anti-proliferative effects by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) method 
The effect of brucine and/or gemcitabine on the proliferation of 
MDA MB-231 cells was determined by MTT assay [21]. Briefly, 
5000 cells were seeded in a 96-well plate and treated with desired 
concentrations of brucine (10, 50, 100, 150, 200, 250 and 300 μM) 
or gemcitabine (0.001, 0.05, 0.1, 10, 25, 50 and 100 μM). 
Combination treatments were performed in three sets.  First set: 
Cells were treated with brucine and gemcitabine at the same time 
for 48 h. Second set:  Cells were pre-treated with gemcitabine for 
12 h and then exposed to brucine for 48 h. Third set: Cells were 
pre-treated with brucine (50,100 and 300 μM) for 12 h and then 
exposed to gemcitabine (25, 50 and 100 μM) for 48 h. Cytotoxicity 
was determined by adding 10 øl of MTT (0.5 mg/ml in PBS) to each 
well and incubated for 4 h. The medium was removed and 100 μl 
DMSO was added to each well and after 10 min of mechanical 
shaking, the optical density was measured at 570 nm in plate 
reader (Spectra Max, M5, Bio-Rad, USA).  
Colony formation assay in soft agar 
The standard colony formation assay was performed as described 
[22]. MDA MB-231 cells (10ï104) were plated in 60 mm culture 
plates and incubated overnight at 37ÀC. The cells were treated 
either brucine (50 and 100 øM) or gemcitabine (25 and 50 øM) 
alone and in combination with both the drugs at the specified 
concentrations for 48 h. After treatment with drugs, the cells were 
harvested, 0.4ï105 cells were counted from each concentration by 
using trypan blue assay and the cells were suspended in 0.3% top 
agar (Difco, Noble agar Detroit, MI) in the medium. Base agar 
(0.5%) was poured in 35 mm culture plates and top agar containing 
cells was poured on the base agar. The cells were incubated at 
37ÀC in CO2 incubator (5% CO2) for three weeks. The medium was 
added every three days. After three weeks, colonies were stained 
with 0.5% crystal violet and washed with PBS to remove excessive 
dye. Stained colonies were counted individually using inverted 
phase microscope (Zeiss, Axiovert 25, Germany).  
In vitro Scratch Assay  
MDA MB-231 cells (5ï104) were seeded in 60 mm culture plates 
and the monolayer of 80% confluent cells were subjected to serum 
starvation for 2 h and treated for 48 h either with brucine (50 and 
100 øM) or gemcitabine (25 and 50 øM) and their combinations. 
After incubation for 48 h, the drug containing medium was 
removed, scratch was created by sterile p200 tip and washed (x2) 
with PBS to remove floating cells and 2% FBS media was added. 
Photographic images were taken at 0, 12, 24 and 48 h using 
inverted phase microscope (Zeiss, Axiovert 25, Germany). Cell 
migration was expressed as the percentage of the gap relative to 
the total area of the cell-free region using Image-J software 
(National Institutes of Health, Bethesda, MD, USA) [23]. 
Western blot analysis 
To detect the expression levels of p65-NF-kB protein by western 
blot analysis. MDA MB-231 cells (1ï106) were seeded in 60 mm 
culture plates and allowed to adhere overnight at 37ÀC. The cells 
were treated either with brucine (300 μM) or gemcitabine (100 μM) 
or combinations of both drugs for 48 h. The cells were washed 
twice with ice-cold PBS buffer (pH 7.4) and incubated with RIPA 
buffer containing protease inhibitor cocktail for 10 min at 4ÀC. The 
cell lysates were centrifuged at 14000 rpm for 10 min at 4ÀC and 
the protein concentration was determined using the Bio-Rad 
protein assay. An equal volume of loading buffer was added to the 
samples and were boiled at 95ÀC for 10 min. Protein (20 øg) 
samples were loaded and separated using 8% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
proteins were transferred onto nitrocellulose membrane. The 
membrane was blocked with 5% non-fat dry milk in 1X TBST buffer 
for 1 h followed by incubation with p65 (NF-kB) primary antibody 
(1:1000 dilutions in TBST) overnight at 4ÀC. After washing with 
TBST, the membrane was incubated with goat anti-rabbit IgG 
conjugated secondary antibody (1:5000 dilutions in TBST) for 1h at 
room temperature followed by washing with TBST. The protein 
bands were determined by incubation with electro-
chemiluminescence (ECL- Bio-Rad) reagent for 1 min. The band 
intensity was determined by Image-J software (National Institutes 
of Health, Bethesda, MD, USA) MDA [24].   
Statistical analysis 
Experimental results are presented as the mean μ standard 
deviation (SD) obtained from three independent experiments. 
Differences were evaluated by the one-way analysis of variance 
(ANOVA) followed by DunnettÊs multiple comparison test. The level 
of significance was set at p ª 0.05. 
Results 
Brucine and gemcitabine treatment suppresses 
proliferation of MDA MB-231 cells  
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To determine whether combination treatment with brucine and 
gemcitabine enhances the inhibition of MDA MB-231 cell 
proliferation MTT assay was performed. Individual treatment with 
brucine or gemcitabine showed significant inhibition of cell 
proliferation in a dose dependent manner.  Cells treated with 
brucine and gemcitabine individually at 200 øM and 100 øM 
suppressed the cell proliferation by 45 and 50% respectively (p ª 
0.001, Fig. 1A, 1B) compared to untreated cells. The IC50 values of 
brucine and gemcitabine in MDA MB-231 cells were 116.4 and 70 
μM respectively. Combination treatment with both brucine and 
gemcitabine at 300 øM and 100 øM showed significant (p ª 0.001) 
decrease in cell proliferation (79%) compared to untreated cells 
indicating an additive effect.   
The inhibition of cell proliferation in the combination of gemcitabine 
and brucine was significantly higher (Figure 2A) than pre-treatment 
with either gemcitabine or brucine (Figures 2B and C). Although, 
inhibition of cell proliferation in cells pre-treated with gemcitabine 
for 12 h followed by brucine treatment were statistically significant 
(p ª 0.001) compared with cells pre-treated with brucine and 
followed by gemcitabine (Figure 2B and 2C). 
 
 
Figure 1: Brucine and gemcitabine suppresses the proliferation of MDA MB-231 cells 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                Figure 2: Treat at same time and pre-treatment with brucine and gemcitabine suppresses the proliferation of MDA MB-231 cells 
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Effect of brucine and/or gemcitabine on anchorage-
independent growth of MDA MB-231 cells 
Soft agar assay was performed to determine the colony formation 
ability of MDA MB-231 cells treated with brucine and/or 
gemcitabine. The number of colonies in untreated cells and cells 
treated with both the agents, alone or in combination are counted 
and summarized in Figure 3. Individual treatment with brucine (100 
øM) and gemcitabine (50 øM) showed significant inhibition in 
colony formation, 29% and 25% respectively compared to 
untreated cells. Combination treatment with 100 øM brucine and 50 
øM gemcitabine resulted in additive inhibition (75%) of colony 
formation compared to treatment with either brucine or gemcitabine 
alone. These results were consistent with the results observed in 
MTT assay.  
 
                                        Figure 3: Effect of brucine and gemcitabine on colony formation of MDA MB-231 cells in soft agar 
Brucine and gemcitabine inhibit the cell migration  
The effect of brucine and/or gemcitabine on MDA MB-231 cell 
migration was measured by in vitro scratch assay. Cell migration 
was reduced by 10% and 20% with individual treatment with 
brucine (100 øM) and gemcitabine (50 øM), respectively (Figure 4). 
However, the cell migration was significantly inhibited (60%) when 
the cells were treated in combination of both the agents (100 øM 
brucine and 50 øM gemcitabine).  These results suggest that in 
combinational therapy shows additive effect in inhibiting the 
migration of MDA MB-231 cells.
 
                                                        Figure 4: Effect of brucine and gemcitabine on cell migration 
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Effect of brucine and/or gemcitabine on the expression 
of NF-kB   
We next investigated whether the inhibitory effect of brucine and 
gemcitabine on breast cancer cell is mediated through the 
alteration of NF-kB expression. Protein extracts of un-treated and 
brucine and gemcitabine treated MDA MB-231 cells were analyzed 
by Western blot assay to assess p65 expression. Cells treated with 
brucine at 300 øM showed significantly (76%) reduced level of p65 
protein expression compared to untreated cells (Figure 5). 
Gemcitabine (100 øM) treatment did not show any effect on p65  
protein expression compared to untreated cells. Combination 
treatment with 300 øM brucine and 100 øM gemcitabine inhibited 
the p65 expression by 62% compared to untreated cells. Therefore 
combination appears to have less inhibitory effect on p65 
expression when compared to brucine treatment alone.  
 
Figure 5: Effect of brucine and gemcitabine on p65 NF-kB expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Plants have been an important source of potent drugs for the 
treatment of many types of diseases including cancer and provide 
leads for the development of novel agents. Combinations of 
phytochemicals with known anticancer drugs have been shown to 
be highly effective [25]. The efficacy of treatment would increase 
and the chance of adverse effects may be lowered due to the use 
of lower concentrations when combined together. The results in the 
present study indicated that brucine in combination with 
gemcitabine significantly decreased the MDA MB-231 breast 
cancer cell proliferation. Brucine has been used as anticancer 
agent in various types of cancers including hepatoma and lung 
cancer [26]. Previous studies indicated that brucine inhibits HepG2 
cells by inducing apoptosis through increased caspase-3 [9]. 
Results of the present study revealed that combination exposure of 
both drugs at same time point exhibited highest inhibition in cell 
proliferation than pre-treatment with either brucine or gemcitabine 
alone. Also pre-treatment with brucine did not show higher 
inhibition whereas pre-treatment with gemcitabine was more 
effective. Breast cancer prognosis can be greatly influenced by 
metastasis. Previous study reported that brucine inhibit the liver 
cancer cell migration by suppressing the hypoxia inducible factor, a 
key transcription factor which is responsible for cell migration and 
invasion [23]. In the present study combination treatment with both 
brucine and gemcitabine exhibited synergistic attenuation in cell 
migration than either agent alone. Anchorage independent growth 
in soft agar assay also showed additive effect. Various reports had 
suggested that chemotherapeutic drugs which targeted the NF-kB 
activity would be helpful in cancer therapy [14]. NF-kB plays a key 
role both in inflammation, cancer cell progression, proliferation, 
invasion, angiogenesis and metastasis [5]. Earlier it was shown 
that brucine suppresses NF-kB activity by inhibiting 
phosphorylation of Ik-Bđ as well as the nuclear translocation of p65 
[20]. Our results have shown that, cells treated with brucine 
significantly inhibited expression of p65 protein, whereas, 
gemcitabine did not show any effect on p65 expression.  
Conclusion 
Overall, the experimental evidence showed that combination 
treatment of brucine and gemcitabine exhibits additive effect in 
inhibiting MDA MB-231 cells. Pre-treatment with brucine and 
gemcitabine or vice versa and alone did not show greater 
advantage when compared to the combination treatment. Further, 
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experimental evidence from this study revealed that alteration of 
cell proliferation, cell survival, migration, and nuclear factor kB 
subunit (p65) protein expression levels were observed after the 
treatment. We consider combined treatment of brucine-
gemcitabine could be a potential anti-proliferative agent for breast 
cancer cells.  
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